Cutaneous graft-versus-host disease

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially life-saving treatment modality. However, many patients who undergo allogeneic HSCT develop graft-versus- host disease (GVHD) of the skin, potentially resulting in significant long-term morbidity. Chronic GVHD may manifest on the skin in many different clinical presentations, including skin fibrosis, and represents a significant treatment challenge that is often compounded by co-morbidities due to GVHD involvement of other organ systems.